Apixaban (Eliquis) is a oral anticoagulant medicine which is used for the prevention of blood clots and prevention of stroke. It is supplied by Bristol Myers Squibb-Pfizer.
It is used to prevent blood clots forming in people who have had total knee or hip replacement surgery and, to help prevent strokes in people who are considered to be at risk of stroke following a diagnosis of Atrial Fibrillation (AF), a condition that causes an irregular and often abnormally fast heart rate which disturbs the heart rhythm.
IN 2011 and 2012, SMC and NICE respectively recommended Apixaban as an option for the prevention of venous thromboembolism in adults after elective hip or knee surgery
In 2013, The National Institute for Health and Clinical Excellence (NICE) and Scottish Medicines Consortium (SMC) recommended Apixaban for preventing stroke and blood clots for people with non valvular atrial fibrillation with 1 or more risk factors.
In 2015, NICE issued guidance(TA 341) for Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism